ATRS - ATRS STOCK NEWS

Halozyme Therapeutics is set to acquire Antares Pharma for $5.60 per share, valuing the transaction at approximately $960 million. This acquisition aims to enhance Halozyme's drug delivery business and diversify its revenue streams through Antares' auto injector platform. The deal is anticipated to be immediately accretive to Halozyme's revenue and non-GAAP earnings in 2022, with significant growth projections into 2027. The merger is backed by both companies' boards and expected to close in the first half of 2022.

Antares Pharma announced the FDA's final approval of TLANDO™ (testosterone undecanoate), an oral testosterone replacement therapy for adult males with hypogonadism. The commercial launch is anticipated in Q2 2022. CEO Robert F. Apple emphasized the product's potential benefits for patients and physicians, supported by an expanded sales force of 108 representatives. The company aims to leverage existing relationships with urologists and endocrinologists to enhance market share alongside its product XYOSTED.

Antares Pharma reported a 23% year-over-year revenue increase, reaching $184.0 million for 2021, with a net income of $46.3 million ($0.26 per diluted share). Q4 2021 revenue was $48.7 million, driven by a 34% increase in prescriptions for XYOSTED. The company anticipates 2022 revenues between $200 million and $220 million, excluding unapproved products. Key developments include positive Phase 1 results for ATRS-1902 and a PDUFA action date for TLANDO set for March 28, 2022. The company plans to invest in R&D while navigating ongoing challenges from the pandemic.

Antares Pharma, a specialty pharmaceutical company, will have its CEO Robert F. Apple present at the Cowen 42nd Annual Healthcare Conference from March 7-9, 2022. He is scheduled to participate in a fireside chat on March 8 at 9:50 AM ET. A webcast will be available on the company's website. Antares Pharma specializes in the development of self-injected pharmaceutical products and has several FDA-approved items, including XYOSTED® and Sumatriptan Injection. The company anticipates launching TLANDO® pending FDA approval.

Antares Pharma, a specialty pharmaceutical company, will release its fourth quarter and full-year 2021 financial results on March 3, 2022, before the market opens. A conference call scheduled for 8:30 AM ET will discuss these results, with dial-in numbers for both domestic and international participants. The call will also be available via a live webcast on the company’s website. Antares focuses on developing self-administered injectable products, with FDA-approved products including XYOSTED and NOCDURNA, and anticipates launching TLANDO pending final FDA approval.

Antares Pharma has announced that the FDA accepted its NDA resubmission for TLANDO® (testosterone undecanoate), targeting a decision by March 28, 2022. The NDA was classified as a Class 1 resubmission, with a two-month review period. TLANDO® has already received tentative approval for testosterone replacement therapy and is expected to launch commercially post final FDA approval. The company aims to leverage strong physician relationships to promote TLANDO® alongside its existing product, XYOSTED, potentially enhancing market share in the testosterone market.

Antares Pharma, Inc. (NASDAQ: ATRS) announced that the FDA granted Fast Track designation for ATRS-1902, a treatment for acute adrenal insufficiency, also known as adrenal crisis. This designation accelerates the development and review process for drugs targeting serious conditions without existing treatment options. Antares plans to submit a 505(b)(2) NDA by year-end, supported by positive Phase I study results showing ATRS-1902's pharmacokinetic profile matches that of the reference drug, Solu-Cortef.

Antares Pharma, Inc. (NASDAQ: ATRS) announced the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Richardson brings over 25 years of HR leadership from various industries and will oversee the company's HR strategy, aiming to enhance employee engagement and diversity initiatives. CEO Robert F. Apple expressed excitement about Richardson's extensive background and its anticipated positive impact on the company's growth and culture. Richardson has held senior HR roles at notable companies and is a U.S. Marine Corps veteran.

Antares Pharma (NASDAQ: ATRS) announced promising Phase I study results for ATRS-1902, aimed at treating adrenal crisis. The study showed that ATRS-1902 delivered a pharmacokinetic profile comparable to Solu-Cortef, with a favorable safety and tolerance profile in 32 healthy adults. The Company plans to advance ATRS-1902 to a pivotal clinical study in Q2 2022 and file a 505(b)(2) NDA with the FDA by year-end, contingent on study success. This development is expected to support future revenue growth and enhance treatment options for adrenal crisis patients.